VYGR
What one share of Voyager Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Our pipeline includes programs for Alzheimer’s disease, or AD; Friedreich’s ataxia, or FA; Parkinson’s disease, or PD; and multiple other diseases of the central nervous system, or CNS.
Voyager Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.58 |
|---|---|
| Profit | −$1.81 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$2.04 |
| Cash and investments | $2.43 |
| Book value | $2.52 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.56 | −$1.59 | $0.20 | −$1.88 | — | $5.31 |
| 2017 | $0.38 | −$2.64 | $0.15 | −$2.44 | — | $4.25 |
| 2018 | $0.24 | −$2.75 | $0.13 | −$0.63 | $0.00 | $1.44 |
| 2019 | $2.91 | −$1.21 | $0.21 | $1.14 | $0.00 | $2.70 |
| 2020 | $4.58 | $0.98 | $0.32 | −$2.91 | $0.00 | $4.13 |
| 2021 | $0.99 | −$1.89 | $0.04 | −$1.46 | $0.00 | $2.51 |
| 2022 | $1.07 | −$1.21 | $0.06 | −$0.39 | — | $1.53 |
| 2023 | $5.61 | $2.97 | $0.07 | $1.68 | — | $5.37 |
| 2024 | $1.39 | −$1.13 | $0.06 | −$0.33 | — | $5.48 |
| 2025 | $0.69 | −$2.04 | $0.04 | −$2.30 | — | $3.32 |